Clinical Trial Update: Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating neoadjuvant sugemalimab plus chemotherapy followed by adjuvant sugemalimab for resectable stage II-IIIA non-small cell lung cancer is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sugemalimab (sugemalimab)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Lung Cancer (NSCLC) | Phase 2 | Status: RECRUITING